Proprietary Technology for Selective Nucleic Acid Recognition
Who we are
Meet our Experts
Filip Rázga, PhD., MPH
Dr Razga has 20+ years of professional experience in oncology with a biotechnology focus in the last decade.
Veronika Némethová, PhD., MPH
Dr Nemethova is an expert in molecular biology and genetics and has 10+ years of professional background in oncology and cancer genetics.
JUDr. Miroslav Ivanovič
Dr Ivanovic provides legal services in the fields of intellectual property rights, commercial and medical law.
What we offer
for selective nucleic acid recognition
Product-driven development of diagnostic and therapeutic modalities mainly for oncology patients.
decrease of target
in cellular uptake
Spontaneous cellular internalization of an ESiNAR-X® platform-based oligonucleotide in
Fibroblasts & Mesenchymal stem cells.
- Mesenchymal stem cells